# Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

> **NCT05627414** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Disitamab Vedotin
- **DRUG:** Sintilimab
- **DRUG:** S-1
- **PROCEDURE:** Intraperitoneal chemotherapy with paclitaxel

## Key facts

- **NCT ID:** NCT05627414
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05627414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05627414, "Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05627414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*